Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Head and Neck Neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    257 result(s) found for: Head and Neck Neoplasms. Displaying page 3 of 13.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001628-23 Sponsor Protocol Number: 2017/2558 Start Date*: 2017-10-17
    Sponsor Name:Gustave Roussy
    Full Title: Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable h...
    Medical condition: Resectable head and neck mucosal melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000391-34 Sponsor Protocol Number: 1200.43 Start Date*: 2011-10-25
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Head & Neck 1 A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metas...
    Medical condition: Recurrent and/or metastatic head and neck squamous cell carcinoma in patients who have progessed after platinum based therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FR (Completed) DE (Completed) GR (Completed) ES (Completed) AT (Completed) CZ (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001976-39 Sponsor Protocol Number: GORTEC-2018-02 Start Date*: 2018-12-14
    Sponsor Name:GORTEC
    Full Title: A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
    Medical condition: Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005188-34 Sponsor Protocol Number: GORTEC2014-03 Start Date*: 2015-04-20
    Sponsor Name:GORTEC
    Full Title: Phase III trial of laryngeal preservation comparating Induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel (TPF) followed by radiotherapy and concomitant administration of radiother...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002403-18 Sponsor Protocol Number: ET12-034 Start Date*: 2013-01-17
    Sponsor Name:Centre Léon Berard
    Full Title: PIK-ORL: A Phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients with metastatic head and neck cancer recurrent or progressive under platin and cetuximab-based chemotherapy
    Medical condition: Patients with metastatic or relapsed head and neck cancer and documented progression or relapse after platin and cetuximab-based chemotherapy (combination or sequential treatment)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002017-37 Sponsor Protocol Number: EFC5512 Start Date*: 2005-03-23
    Sponsor Name:Sanofi-Synthelabo Research
    Full Title: Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer
    Medical condition: Oncology: Advanced Head and Neck cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10025960 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IT (Prematurely Ended) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002163-22 Sponsor Protocol Number: NANORAY-312 Start Date*: 2022-07-13
    Sponsor Name:Nanobiotix SA
    Full Title: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly P...
    Medical condition: Locally Advanced Head & Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Prematurely Ended) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003589-10 Sponsor Protocol Number: D419LC00001 Start Date*: 2015-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic S...
    Medical condition: Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) PL (Completed) AT (Completed) RO (Completed) FR (Completed) PT (Completed) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004093-21 Sponsor Protocol Number: AT148003 Start Date*: 2021-12-14
    Sponsor Name:ALX Oncology Inc.
    Full Title: A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-03)
    Medical condition: Patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003786-13 Sponsor Protocol Number: 20050251 Start Date*: 2007-03-30
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) HU (Completed) BE (Completed) FR (Completed) SE (Completed) PT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-022924-57 Sponsor Protocol Number: 17176 Start Date*: 2011-08-17
    Sponsor Name:Radiumhemmet Karolinska University Hospital [...]
    1. Radiumhemmet Karolinska University Hospital
    2. Radiumhemmet
    Full Title: Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of...
    Medical condition: Patients with relapsed or metastatic squamous cell carcinoma of the head and neck Previously not treated for relapsed or metastatic SCCHN.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005014-12 Sponsor Protocol Number: 1122P1811 Start Date*: 2012-06-13
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, Immune Response, and Clinical Efficacy of Cancer Peptide Vaccine S-488210 in Patients with Unresectable Locoregionally Recurrent and/or Metas...
    Medical condition: Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005910-17 Sponsor Protocol Number: KKSH176 Start Date*: 2021-06-01
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned fo...
    Medical condition: Recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002546-74 Sponsor Protocol Number: ADRISK Start Date*: 2018-06-21
    Sponsor Name:University Leipzig
    Full Title: Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized...
    Medical condition: Advanced primary resectable stage III, IVA/B head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001144-18 Sponsor Protocol Number: MS202359_0002 Start Date*: 2022-09-29
    Sponsor Name:MERCK HEALTHCARE KGaA
    Full Title: A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement...
    Medical condition: Resected squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000773-31 Sponsor Protocol Number: E7050-702 Start Date*: 2011-12-20
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head an...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004655-31 Sponsor Protocol Number: 1143-SCCHN-202 Start Date*: 2015-03-25
    Sponsor Name:Debiopharm International S.A.
    Full Title: Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck.
    Medical condition: Squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003934-25 Sponsor Protocol Number: 3475-412 Start Date*: 2017-03-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous...
    Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004662-19 Sponsor Protocol Number: AT148004 Start Date*: 2022-01-05
    Sponsor Name:ALX Oncology Inc.
    Full Title: A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-04)
    Medical condition: Patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000579-20 Sponsor Protocol Number: CINC280X2104 Start Date*: 2014-07-24
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNS...
    Medical condition: Head and neck squamous cell carcinoma. Colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) IT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:19:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA